Radiopharmaceutical Therapy Roundtable

On November 12, 2024, ASTRO hosted the second Radiopharmaceutical Therapy Roundtable. ASTRO Board members Jeff Michalski, MD, MBA, FASTRO, and Chelsea Pinnix, MD, PhD, along with Ana Kiess, MD, PhD, chair, and Freddie Escorcia, MD, PhD, vice-chair of the ASTRO RPT Committee, led the meeting with support from Roundtable members Cellectar Biosciences and AstraZeneca. Topics included the status of the workforce and associated training needs, research and practice readiness. Other industry members that attended in person (pictured above) and online included Bayer, Elekta, Lantheus, MIM Software, NorthStar Medical Radioisotopes, Novartis Pharmaceuticals Corporation, OncoBeta, Perspective Therapeutics, Rayzebio, Reflexion, Sun Nuclear, a Mirion Medical Company, Theragenics, Varian and Voximetry.

In early 2023, ASTRO convened RPT industry leaders and ASTRO members, including academic and community practice physicians and physician scientists, for a strategic dialogue on the future of RPT. The meeting yielded key insights and priority areas that will drive ASTRO’s activities, including the development of a Radiopharmaceutical Roundtable, allowing vendors to help shape and prioritize the strategic direction of ASTRO’s RPT activities.

The main goal of the Roundtable is to expand the dialogue between radiation oncology professionals and industry thought leaders and extend the level of engagement and honest conversation. ASTRO is eager to undertake some of the critical topics that have emerged and work together to collaboratively address these priority areas with the Roundtable members below.